New kidney drug QRX-3 shows promise in slowing disease progression
Disease control
Completed
This completed Phase 2 trial tested QRX-3, a drug that boosts NAD activity in kidney cells to reduce damage and improve function. 127 adults with chronic kidney disease stages 3-5 took part over 12 months. Researchers measured changes in kidney function and protein levels in urin…
Phase: PHASE2 • Sponsor: Ebima Clifford Okundaye • Aim: Disease control
Last updated Jun 26, 2026 14:36 UTC